Interferon-alpha treatment induces depression-like behaviour accompanied by elevated hippocampal quinolinic acid levels in rats

Behavioural Brain Research

Volumn 293, Issue , 2015, Pages 166-172

  Fischer, Christina Weide ^a   Eskelund, Amanda ^a   Budac, David P ^b   Tillmann, Sandra ^a   Liebenberg, Nico ^a   Elfving, Betina ^a   Wegener, Gregers ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b LUNDBECK RESEARCH USA   (United States)

Author keywords

Animal models; Depression; Interferon alpha; Tryptophan kynurenine pathway

Indexed keywords

3 HYDROXYKYNURENINE; ALPHA INTERFERON; CELECOXIB; IMIPRAMINE; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; NICOTINAMIDE; QUINOLINIC ACID; RECOMBINANT ALPHA INTERFERON; SACCHARIN; SODIUM CHLORIDE; TRYPTOPHAN; ANTIDEPRESSANT AGENT; SWEETENING AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; ENZYME ACTIVATION; FLUID INTAKE; FOOD INTAKE; FOOD PREFERENCE; FORCED SWIM TEST; HIPPOCAMPUS; IMMOBILIZATION; LOCOMOTION; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; TREATMENT DURATION; TRYPTOPHAN BRAIN LEVEL; WEIGHT GAIN; ANIMAL; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; ELECTROCHEMISTRY; ILLNESS BEHAVIOR; LIQUID CHROMATOGRAPHY; METABOLISM; NONPARAMETRIC TEST; PATHOLOGY; PSYCHOLOGY; SPRAGUE DAWLEY RAT; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS; CHROMATOGRAPHY, LIQUID; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCHEMISTRY; FOOD PREFERENCES; HIPPOCAMPUS; ILLNESS BEHAVIOR; INTERFERON-ALPHA; MALE; QUINOLINIC ACID; RATS; RATS, SPRAGUE-DAWLEY; SACCHARIN; STATISTICS, NONPARAMETRIC; SWEETENING AGENTS; SWIMMING; TRYPTOPHAN;

EID: 84938080484     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.07.015     Document Type: Article

References (37)

1. Basu G.D., Tinder T.L., Bradley J.M., Tu T., Hattrup C.L., Pockaj B.A., et al. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J. Immunol. 2006, 177(4):2391-2402.
2. Bonaccorso S., Marino V., Puzella A., Pasquini M., Biondi M., Artini M., et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J. Clin. Psychopharmacol. 2002, 22(1):86-90.
3. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 2002, 26(5):643-652.
4. Capuron L., Neurauter G., Musselman D.L., Lawson D.H., Nemeroff C.B., Fuchs D., et al. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol. Psychiatry 2003, 54(9):906-914.
5. Comai S., Cavalletto L., Chemello L., Bernardinello E., Ragazzi E., Costa C.V., et al. Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C. Pharmacol. Res.: Off. J. Ital. Pharmacol. Soc. 2011, 63(1):85-92.
6. De La Garza R., 2nd, Asnis G.M., Pedrosa E., Stearns C., Migdal A.L., Reinus J.F., et al. Recombinant human interferon-alpha does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2005, 29(5):781-792.
7. Dorr R.T. Interferon-alpha in malignant and viral diseases. A review. Drugs 1993, 45(2):177-211.
8. Dunn A.L., Crnic L.S. Repeated injections of interferon-alpha A/D in Balb/c mice: behavioral effects. Brain Behav. Immun. 1993, 7(1):104-111.
9. Elgarf A.S., Aboul-Fotouh S., Abd-Alkhalek H.A., El Tabbal M., Hassan A.N., Kassim S.K., et al. Lipopolysaccharide repeated challenge followed by chronic mild stress protocol introduces a combined model of depression in rats: reversibility by imipramine and pentoxifylline. Pharmacol. Biochem. Behav. 2014, 126:152-162.
10. Friebe A., Horn M., Schmidt F., Janssen G., Schmid-Wendtner M.H., Volkenandt M., et al. Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma. Psychosomatics 2010, 51(6):466-473.
11. Fuchs D., Moller A.A., Reibnegger G., Stockle E., Werner E.R., Wachter H. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J. Acquir. Immune Defic. Syndr. 1990, 3(9):873-876.
12. Fuchs D., Norkrans G., Wejstal R., Reibnegger G., Weiss G., Weiland O., et al. Changes of serum neopterin, beta 2-microglobulin and interferon-gamma in patients with chronic hepatitis C treated with interferon-alpha 2b. Eur. J. Med. 1992, 1(4):196-200.
13. Guo J.Y., Li C.Y., Ruan Y.P., Sun M., Qi X.L., Zhao B.S., et al. Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. Eur. J. Pharmacol. 2009, 612(1-3):54-60.
14. Kohler O., Benros M.E., Nordentoft M., Farkouh M.E., Iyengar R.L., Mors O., et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 2014, 71(12):1381-1391.
15. Krass M., Wegener G., Vasar E., Volke V. The antidepressant action of imipramine and venlafaxine involves suppression of nitric oxide synthesis. Behav. Brain Res. 2011, 218(1):57-63.
16. Krause D.L., Riedel M., Muller N., Weidinger E., Schwarz M.J., Myint A.M. Effects of antidepressants and cyclooxygenase-2 inhibitor on cytokines and kynurenines in stimulated in vitro blood culture from depressed patients. Inflammopharmacology 2012, 20(3):169-176.
17. Loftis J.M., Wall J.M., Pagel R.L., Hauser P. Administration of pegylated interferon-alpha-2a or -2b does not induce sickness behavior in Lewis rats. Psychoneuroendocrinology 2006, 31(10):1289-1294.
18. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav. Pharmacol. 1997, 8(6-7):523-532.
19. Makino M., Kitano Y., Hirohashi M., Takasuna K. Enhancement of immobility in mouse forced swimming test by treatment with human interferon. Eur. J. Pharmacol. 1998, 356(1):1-7.
20. Makino M., Kitano Y., Komiyama C., Takasuna K. Human interferon-alpha increases immobility in the forced swimming test in rats. Psychopharmacol. (Berl.) 2000, 148(1):106-110.
21. Mazarei G., Budac D.P., Lu G., Adomat H., Tomlinson Guns E.S., Moller T., et al. Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease. J. Neurochem. 2013, 127(6):852-867.
22. Miyaoka H., Otsubo T., Kamijima K., Ishii M., Onuki M., Mitamura K. Depression from interferon therapy in patients with hepatitis C. Am. J. Psychiatry 1999, 156(7):1120.
23. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A.K., Penna S., Goodkin R.S., et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 2001, 344(13):961-966.
24. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34(1):13-25.
25. Ping F., Shang J., Zhou J., Zhang H., Zhang L. 5-HT(1A) receptor and apoptosis contribute to interferon-alpha-induced depressive-like behavior in mice. Neurosci. Lett. 2012, 514(2):173-178.
26. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol. 1978, 47(4):379-391.
27. Raison C.L., Dantzer R., Kelley K.W., Lawson M.A., Woolwine B.J., Vogt G., et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol. Psychiatry 2010, 15(4):393-403.
28. Reyes Ocampo J., Lugo Huitron R., Gonzalez-Esquivel D., Ugalde-Muniz P., Jimenez-Anguiano A., Pineda B., et al. Kynurenines with neuroactive and redox properties: relevance to aging and brain diseases. Oxid. Med. Cell. longev. 2014, 649:909.
29. Rios C., Santamaria A. Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem. Res. 1991, 16(10):1139-1143.
30. Sammut S., Goodall G., Muscat R. Acute interferon-alpha administration modulates sucrose consumption in the rat. Psychoneuroendocrinology 2001, 26(3):261-272.
31. Steiner J., Walter M., Gos T., Guillemin G.J., Bernstein H.G., Sarnyai Z., et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission. J. Neuroinflammation 2011, 8:94.
32. Stone T.W. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 1993, 45(3):309-379.
33. Wang J., Dunn A.J., Roberts A.J., Zhang H. Decreased immobility in swimming test by homologous interferon-alpha in mice accompanied with increased cerebral tryptophan level and serotonin turnover. Neurosci. Lett. 2009, 452(2):96-100.
34. Wichers M.C., Kenis G., Koek G.H., Robaeys G., Nicolson N.A., Maes M. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. J. Psychosom. Res. 2007, 62(2):207-214.
35. Wichers M.C., Koek G.H., Robaeys G., Verkerk R., Scharpe S., Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol. Psychiatry 2005, 10(6):538-544.
36. Yamano M., Yuki H., Yasuda S., Miyata K. Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice. J. Pharmacol. Exp. Ther. 2000, 292(1):181-187.
37. Zheng L.S., Hitoshi S., Kaneko N., Takao K., Miyakawa T., Tanaka Y., et al. Mechanisms for interferon-alpha-induced depression and neural stem cell dysfunction. Stem Cell Rep. 2014, 3(1):73-84.